Clinical trial
A First Time in Human Phase 1 Open-Label Study of the Safety, Tolerability, and Immunogenicity of COVIDITY Vaccine Administered by Needle-free Intradermal Injection or Needle-free Intramuscular Injection in Healthy Adults (COVIDITY-001)
NCT05047445 is registered in ClinicalTrials.gov with Scancell Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A First Time in Human Phase 1 Open-Label Study of the Safety, Tolerability, and Immunogenicity of COVIDITY Vaccine Administered by Needle-free Intradermal Injection or Needle-free Intramuscular Injection in Healthy Adults (COVIDITY-001)
- Lead sponsor
- Scancell Ltd
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- October 1, 2021
- Completion date
- December 31, 2022
- Enrollment
- 80 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.